Holen Sie sich die Stockscreener-App
5.48
0.54%
-0.03
Handel nachbörslich:
5.47
-0.01
-0.18%
Curevac N V Aktie (CVAC) Neueste Nachrichten
Is CureVac N.V. stock bottoming out2025 Trading Recap & Consistent Growth Stock Picks - Newser
Investors Hope for Bounce in CureVac N.V. After Selloff2025 Market Trends & High Conviction Buy Zone Picks - metal.it
Published on: 2025-08-17 02:22:48 - Newser
What to do if you’re stuck in CureVac N.V.2025 Year in Review & Daily Momentum Trading Reports - Newser
Will breakout in CureVac N.V. lead to full recoveryJuly 2025 Spike Watch & Accurate Buy Signal Alerts - Newser
CureVac Reports Financial Losses in Mid-2025 - msn.com
Is it time to cut losses on CureVac N.V.Market Movers & Fast Entry High Yield Tips - Newser
Will CureVac N.V. price bounce be sustainableJuly 2025 WrapUp & Verified Chart Pattern Signals - Newser
CureVac N.V. Stages Intraday Comeback — Trend Change2025 Institutional Moves & High Accuracy Trade Signal Alerts - sundaytimes.kr
Is a relief rally coming for CureVac N.V. holders2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
How high can CureVac N.V. stock goWeekly Investment Report & Free Risk Controlled Daily Trade Plans - Newser
CureVac's Q2 Pre-Tax Loss Narrows, Revenue Falls - MarketScreener
Earnings Flash (CVAC) CureVac Posts Q2 Revenue 1.2M Euros, vs. FactSet Est of 3.3M Euros - MarketScreener
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates | CVAC Stock News - GuruFocus
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - ACCESS Newswire
$740M Patent Settlement: CureVac Resolves Pfizer Dispute and Agrees to BioNTech Acquisition Deal - Stock Titan
How does CureVac N.V. compare to its peersExit Point & Risk Managed Investment Strategies - thegnnews.com
Is CureVac N.V. part of any ETF2025 Short Interest & AI Driven Stock Price Forecasts - sundaytimes.kr
Is There Enough Volume to Lift CureVac N.V.Weekly Market Report & Free Long-Term Investment Growth Plans - newsyoung.net
CureVac (CVAC) to Release Earnings on Thursday - Defense World
How CureVac N.V. stock performs during market volatilityPrice Forecast Based on AI Analysis - Newser
CureVac NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
CureVac N.V. (NASDAQ:CVAC) Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
mRNA Cancer Vaccine Market Is Going to Boom | Major Giants BioNTech, Moderna, CureVac, Gilead Sciences - newstrail.com
Key resistance and support levels for CureVac N.V.High Return Strategy with Low Risk - Newser
Analyzing CureVac (NASDAQ:CVAC) & ARAVIVE (NASDAQ:ARAV) - Defense World
Can CureVac N.V. keep up with sector leadersSmart Money ROI Picks - sisain.net
GSK set to get $500 million from settlement of mRNA lawsuit - The Economic Times
Can a trend reversal in CureVac N.V. lead to recoverySmart Swing Picks with Confirmed Signals - Newser
BioNTech (BNTX) Settles mRNA Patent Dispute with CureVac for US$370 Million - Yahoo Finance
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal - BioPharma Dive
Drawdown in CureVac N.V. May Be Nearing EndFast Gaining Stock Screener Reports Released - beatles.ru
GSK Secures $370 Million In MRNA Patent Settlement Windfall - Finimize
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues
CureVac (CVAC) Secures $740M from Patent Settlement with Pfizer and BioNTech - GuruFocus
GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation - MarketScreener
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha
GSK to be paid up to £370 million after patent row settles in US - uk.finance.yahoo.com
GSK: $370m received as part of CureVac/BioNTech agreement - MarketScreener
mRNA rivals call truce as BioNTech prepares CureVac takeover - MarketScreener
GSK wins settlement, future royalties in CureVac mRNA patent dispute - MarketScreener
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement - Bloomberg.com
GSK Reaches $500M Agreement Over Covid-19 Jab Patent Row - AInvest
GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement - Nasdaq
Will CureVac N.V. stock benefit from AI tech trendsFast Gaining Stock Screener Reports Released - metal.it
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update - The Manila Times
Is CureVac N.V. a good long term investmentFree Investment Portfolio Suggestions - Jammu Links News
BioNTech's Q2 revenues double on higher COVID vaccine sales - MarketScreener
Bullish Candlestick Pattern Forms in CureVac N.V.AI Based High Gain Watchlist Scanner Shared - beatles.ru
What is CureVac N.V. company’s growth strategyMassive wealth growth - Jammu Links News
Should I hold or sell CureVac N.V. stock in 2025Superior portfolio returns - Jammu Links News
What makes CureVac N.V. stock price move sharplyHigh-return market picks - Jammu Links News
When is CureVac N.V. stock expected to show significant growthGet expert advice on portfolio optimization - Jammu Links News
CureVac N.V. Stock Analysis and ForecastMaximize gains with data-driven stock picks - Jammu Links News
How does CureVac N.V. generate profit in a changing economyFree Stock Market Trend Analysis - Jammu Links News
How volatile is CureVac N.V. stock compared to the marketStay ahead with daily market updates - Jammu Links News
Does CureVac N.V. stock perform well during market downturnsGet daily expert analysis for smarter investing - Jammu Links News
What are analysts’ price targets for CureVac N.V. in the next 12 monthsUnlock daily stock market insights for success - Jammu Links News
Is it the right time to buy CureVac N.V. stockSignificant capital appreciation - Jammu Links News
How strong is CureVac N.V. company’s balance sheetRetirement Planning Signals To Watch Now - jammulinksnews.com
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):